Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 9Capecitabine 7durvalumab 6pembrolizumab 4tremelimumab 3S 1 (combination) 3Nivolumab 3AZD 6244 3Ramucirumab 2Fluorouracil 2130-nm albumin-bound paclitaxel 2vandetanib 1trifluridine tipiracil drug combination 1trametinib 1tocilizumab 1titanium silicide 1sacituzumab govitecan 1poly ICLC 1futibatinib 1fludarabine 1cemiplimab 1binimetinib 1aflibercept 1Tegafur 1TAS-116 1Psilocybin 1Peptides 1Oxaliplatin 1NUC-1031 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Biliary Tract Neoplasms × CA-4948 × Clear all
NCT07107750 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Washington University School of Medicine

Phase 1 Recruiting
48 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡